Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
500.00    0.60 (0.12%)
Bid:
498.00
Ask:
500.50
Spread: 2.50 (0.502%)
Market Cap: £1.35b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Director/PDMR Shareholding

29 Apr 2014 13:20

RNS Number : 7858F
Chemring Group PLC
29 April 2014
 



FOR IMMEDIATE RELEASE 29 APRIL 2014

 

Chemring Group PLC

Notification of Performance Share Plan Awards

 

 

On 28 April 2014, conditional awards over ordinary shares of 1 pence each in Chemring Group PLC ("Shares" and the "Company") were made to certain directors and other persons discharging managerial responsibilities ("PDMRs") as follows.

Name of director/PDMRs

No. of Shares under the award

 

Mark Papworth

307,112

Steve Bowers

193,965

Sarah Ellard

139,978

Juan Navarro

106,994

 

The awards were granted under the Chemring Group Performance Share Plan 2006.

No consideration was paid for the grant of the awards and no consideration is due on the vesting of the awards.

The awards will ordinarily vest on the third anniversary of grant subject to the grantee's continued service and to the extent performance conditions are satisfied.

The performance conditions applying to the awards are based as to one half of each award on the Company's adjusted earnings per share growth ("EPS") over three financial years of the Company, starting with the current financial year, and as to the other half of each award on the Company's total shareholder return ("TSR") performance over the same three year performance period.

 

No portion of the EPS element shall vest unless the compound annual growth rate ("CAGR") in EPS over the performance period is at least 5% p.a., for which one quarter of the EPS element may vest rising on a straight-line basis for full vesting of the EPS element where the CAGR in EPS over the performance period is 10% p.a. or greater.

 

The base EPS figure for the purposes of such growth calculations (for the year ended 31 October 2013) will be calculated on a proforma basis to take account of the Company's recently announced proposed disposal of the Company's European Munitions Business (Mecar and Simmel). Such figure shall be externally validated by the Company's auditors, Deloitte.

 

The proforma base EPS figure shall be determined by the Remuneration Committee no later than 31 October 2014, with an appropriate adjustment to reflect the reduction in interest charges achieved following the proposed repayment of loan notes in the current year, and will be disclosed in the Annual Report on Directors' Remuneration for the current financial year of the Company.

 

As previously disclosed, in relation to the TSR element, the performance condition will compare the Company's TSR over the performance period against the TSR performance of a comparator group of companies.

 

No portion of the TSR element shall vest unless the Company's TSR performance over the performance period relative to the TSR performance of the comparator group is at least median performance, for which one quarter of the TSR element may vest, rising on a straight-line basis to full vesting of the TSR element for upper quartile ranking TSR performance or better.

 

The Company was informed of the above transactions on 28 April 2014.

This notification is being made in accordance with DTR 3.1.4(a).

 

Enquiries:

Sarah Ellard

Group Legal Director & Company Secretary

Chemring Group PLC

01489 881880

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFLFSAIAFIS
Date   Source Headline
3rd Jun 20264:00 pmRNSHolding(s) in Company
2nd Jun 20267:02 amRNSDirectorate change
2nd Jun 20267:00 amRNSInterim results
1st Jun 20267:00 amRNSTotal Voting Rights
28th May 20262:36 pmRNSHolding(s) in Company
22nd May 20269:15 amRNSHolding(s) in Company
21st May 20267:00 amRNSHolding(s) in Company
14th May 20267:00 amRNSHolding(s) in Company
1st May 20267:00 amRNSHolding(s) in Company
1st May 20267:00 amRNSTotal Voting Rights
1st Apr 20267:00 amRNSTotal Voting Rights
31st Mar 20263:46 pmRNSDirector/PDMR Shareholding
19th Mar 202611:00 amRNSHolding(s) in Company
4th Mar 20267:00 amRNSAppointment of non-executive director
2nd Mar 20269:15 amRNSTotal Voting Rights
20th Feb 20262:48 pmRNSResult of AGM
20th Feb 20267:00 amRNSAGM Update
16th Feb 20267:00 amRNSHolding(s) in Company
9th Feb 20267:00 amRNSHolding(s) in Company
2nd Feb 20267:00 amRNSTotal Voting Rights
23rd Jan 20264:41 pmRNSDirector/PDMR Shareholding
12th Jan 20261:35 pmRNSNotice of AGM
2nd Jan 202610:29 amRNSTotal Voting Rights
19th Dec 202511:53 amRNSHolding(s) in Company
19th Dec 202511:53 amRNSHolding(s) in Company
18th Dec 20257:00 amRNSBlock listing Interim Review
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
15th Dec 20258:42 amRNSTransaction in Own Shares
12th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20253:01 pmRNSAdditional Listing - Replacement
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 202512:41 pmRNSDirector/PDMR Shareholding
10th Dec 202512:40 pmRNSDirector/PDMR Shareholding
10th Dec 202512:40 pmRNSDirector/PDMR Shareholding
10th Dec 202512:38 pmRNSDirector/PDMR Shareholding
10th Dec 202512:36 pmRNSDirector/PDMR Shareholding
10th Dec 202512:36 pmRNSDirector/PDMR Shareholding
10th Dec 20257:00 amRNSAdditional Listing
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20254:23 pmRNSDirector/PDMR Shareholding
9th Dec 20257:00 amRNSResults for the year ended 31 October 2025
9th Dec 20257:00 amRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
5th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.